Vertex, once king of hep C category, bows out as new drugs eclipse Incivek

Biotech Vertex ($VRTX) has pulled the plug on work in the hepatitis C arena, an area it was expected to dominate with its Incivek until Gilead Sciences ($GILD) redefined the category with Sovaldi, a drug now expected to become the top seller of all time. Even with Incivek fading away, Vertex has continued work in the area, but yesterday said it would out-license its remaining hep C drug, VX-135, and focus its efforts on cystic fibrosis, FierceBiotech reports. Story | More

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…